Exenatide 2 MG Injection [Bydureon] for Insulin Resistance

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Insulin Resistance+3 MoreExenatide 2 MG Injection [Bydureon] - Drug
Eligibility
18 - 69
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new medication can help people with spinal cord injury by improving glycemic control and inducing weight loss.

Eligible Conditions
  • Insulin Resistance
  • Spinal Cord Injury
  • Obesity
  • Prediabetes

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: Baseline, Week 13, Week 26

Week 26
Body Fat
Body Weight
Glycated Hemoglobin (HbA1C)
Homeostatic Model Assessment of Beta-Cell Function (HOMA-B)
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Side Effects for

Exenatide
38%Death
This histogram enumerates side effects from a completed 2017 Phase 4 trial (NCT02058940) in the Exenatide ARM group. Side effects include: Death with 38%.

Trial Design

1 Treatment Group

Exenatide 2 MG Injection [Bydureon]
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Exenatide 2 MG Injection [Bydureon] · No Placebo Group · Phase 4

Exenatide 2 MG Injection [Bydureon]
Drug
Experimental Group · 1 Intervention: Exenatide 2 MG Injection [Bydureon] · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, week 13, week 26

Who is running the clinical trial?

James J. Peters Veterans Affairs Medical CenterLead Sponsor
53 Previous Clinical Trials
3,001 Total Patients Enrolled
1 Trials studying Insulin Resistance
68 Patients Enrolled for Insulin Resistance
Kessler Institute for RehabilitationIndustry Sponsor
22 Previous Clinical Trials
1,190 Total Patients Enrolled

Eligibility Criteria

Age 18 - 69 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: